Trial Profile
The Comparison of Antiarrhythmic and Myocardial Protective Effect Between Lidocaine, Dexmedetomidine, and Their Combined Infusion in Subjects Undergoing Coronary Artery Bypass Graft
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Dexmedetomidine (Primary) ; Lidocaine (Primary)
- Indications Arrhythmias; Myocardial infarction; Unstable angina pectoris
- Focus Biomarker; Pharmacodynamics
- 26 Sep 2012 New trial record